              
defaultWritten evidence submitted bydefault the defaultBioIndustrydefault Association (BIA)default (AMR0026)default&#xa0;
defaultAbout the BIA
default&#xa0;
defaultThe 
defaultBioIndustry
default Association (BIA) is the trade association for innovative bioscience companies. The majority of our members are healthcare focused companies researching and developing new products and technologies to treat areas of unmet medical need. These range from large global biopharmaceuticals to small, pre-revenue companies operating at the translation interface between academia and industry. 
default&#xa0;
defaultThe BIA has engaged with its membership in order to provide an informed response to this inquiry. 
default&#xa0;
defaultThe BIA response 
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
defaultNovember 2013
default&#xa0;
defaultAppendixdefault&#xa0;
defaultThe below table lists brief details of some of the business-led projects which have been awarded Biomedical Catalyst funding, following an application process and subject to conditions, which relate to the development of new antibiotics, anti-
defaultinfectives
default and other research of relevance to the issue of AMR. These are projects across all application stages (feasibility, early stage and late stage) and from funding rounds one, two and three. 
default&#xa0;
defaultCompanydefaultGrant amountdefaultProject costdefaultProject duration (months)defaultBrief descriptiondefaultAbsynth
default Biologics Ltd
default£150,000
default£201,103
default12
defaultBuilding a product pipeline – establishing the commercial potential of new products [innovative approaches to antibacterial vaccines] 
defaultAbsynth
default Biologics Ltd
default£2,013,706
default£3,049,019
default36
defaultStaphylococcus 
defaultaureus
default infections - development of a novel, effective vaccine
defaultAi2 Ltd
default£150,000
default£205,491
default12
defaultAssessing the feasibility of developing Ai2's novel anti-infective peptide technology for topical anti-fungal applications
defaultApplied 
defaultNanodetectors
default Ltd
default£149,709
default£199,612
default12
defaultPoint of care exhaled breath test for the diagnosis of community acquired pneumonia
defaultBase4 Innovation Ltd
default£2,250,000
default£7,214,060
default36
defaultA rapid, highly sensitive, adaptable diagnostic for broad spectrum pathogen screening
default&#xa0;
defaultBlueberry Therapeutics Ltd
default£150,000
default£213,944
default12
defaultDevelopment of a new class of bacterial resistance inhibitors for the treatment of multi-drug resistant infection
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
defaultCantab
default Biopharmaceuticals Limited
default£2,321,884
default£3,869,807
default30
defaultAddressing multi-drug resistant (MDR) Gram-negative bacterial infections by enhanced antibiotic uptake
defaultDiscuva
default Ltd
default£1,620,000
default£2,700,000
default24
defaultDiscovery of new, commercially valuable antibiotics to treat bacterial infections
defaultELISHA Systems Ltd
default£358,956
default£717,956
default30
defaultPhage 
defaultlysin
default biosensor detection of MRSA: point of care prototype: PROMPT-Plus
defaultEnigma Diagnostics Ltd
default£148,338
default£197,785
default4
defaultResonant sensing, a novel form of DNA detection for low-cost highly informative tests; construction of an assay for multidrug resistant TB and bovine TB
defaultIndigix
default Ltd
default£150,000
default£200,000
default12
defaultDendrimer
default based drug for life threatening infectious diarrhoeal diseases
defaultMicroPharm
default Ltd
default£2,067,535
default£2,599,535
default36
defaultUse of ovine polyclonal antibodies to treat severe 
defaultClostridium 
defaultdifficile
default infections
defaultProteinLogic
default Ltd
default£76,922
default£102,562
default9
defaultFeasibility of developing a novel biomarker signature as an innovative diagnostic for tuberculosis (TB)
defaultUnion Life Sciences Ltd
default£150,000
default£262,936
default12
defaultNovel inhibitors for the treatment of infectious disease
defaultValevia
default UK
default£150,000
default£204,353
default10
defaultA novel agent for the treatment of 
defaultC. 
defaultdifficile
default infection
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default 
defaultA recent POST note provides a succinct overview for example: 
defaulthttp://www.parliament.uk/briefing-papers/POST-PN-446.pdf
default 
default Antibiotics Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance, 
defaulthttp://cid.oxfordjournals.org/content/early/2013/04/16/cid.cit152.full
default 
default&#xa0;
default 
defaulthttp://www.roche.com/media/media_releases/med-cor-2013-11-04.htm
default 
defaulthttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf
default 
defaulthttp://www.battlingsuperbugs.com/gain-act.html
default 
default 
defaulthttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm320643.htm
default 
default This proposal was contained within the Strategy for UK Life Sciences.
default 
defaulthttp://www.redxpharma.com/about-us-subsidiaries-redx-anti-infectives.php
default 
defaulthttp://www.redxpharma.com/news-article-20130507.php?filter=Show_All
default 
defaulthttp://www.bionow.co.uk/events/bioinfect2013.aspx
default 
defaulthttp://www.bioindustry.org/document-library/bia-ey-state-of-the-nation-report/
default 
defaulthttp://www.bioindustry.org/document-library/bia-ey-state-of-the-nation-report/
default 
defaulthttp://www.bioindustry.org/policy-and-regulation/biomedical-catalyst/
default 
defaulthttp://www.pherecydes-pharma.com/files/120118%20DGA%20Pherecydes%20ENG.pdf
default 
defaulthttp://www.ampliphibio.com/news/47-ampliphi-signs-global-r-d-agreement-with-us-army-to-develop-bacteriophage-therapies-to-treat-resistant-bacterial-infections.html
default